Benzinga.com15d
Decoding Biogen's Options Activity: What's the Big Picture?
Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...
Nature6y
Milestones in multiple sclerosis: Biogen’s commitment to advancing the field
1 Pegylated IFN β-1a (PLEGRIDY®, Biogen) was US Food and Drug Administration (FDA)– and European Medicines Agency (EMA)–approved in 2014. Establishing new more holistic methods to evaluate ...
Benzinga.com1mon
Biogen Options Trading: A Deep Dive into Market Sentiment
Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...
Nasdaq1mon
Forecasting The Future: 10 Analyst Projections For Biogen
Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...
CNN1y
Biogen Inc.
Biogen, Inc. is a biopharmaceutical company ... Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM ...
Nasdaq21d
What the Options Market Tells Us About Biogen
Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...